Source: Eur Respir J 2009; 33: 153-159
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Restrepo M. I., Mortensen E. M., Waterer G. W., Wunderink R. G., Coalson J. J., Anzueto A.. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33: 153-159

Member's Comments

No comment yet.

Related content which might interest you: Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia Source: Eur Respir J 2009; 33: 142-147 Year: 2009 Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression Source: Eur Respir J 2012; 40: 1201-1210 Year: 2012 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007